June 23, 2020
Quit Genius, a digital addiction-recovery program, has extended its platform to support alcohol and opioid addictions.
The program is designed for enterprise and health plan customers in the U.S. to help their employees recover from addiction.
Fees are paid for by the user’s employer or health plan. Employers are charged an annual fee for each participant that actually enrolls in the program.
American Well CEO Roy Schoenberg shows off the new cart at HIMSS19. (Photo by Jonah Comstock)
February 14, 2019
At HIMSS19, telehealth platform company American Well unveiled the American Well 250 cart, a telehealth cart that allows physicians and patients in a hospital to connect to a wide range of specialists. The product is the first fruit of American Well’s acquisition of Avizia in April of last year.
Additionally at the show, American Well announced an expanded partnership with behavioral health-...
December 3, 2018
The FDA has announced the winners of the opioid addiction innovation challenge the agency launched last May. Out of more than 250 applications from medical device developers, the FDA selected eight winners.
"While these products will not automatically receive marketing authorization from the FDA, the device developers will receive increased interaction with CDRH experts, guidance for clinical...
October 19, 2018
WEconnect, maker of an app that helps addiction patients through their first year after substance abuse treatment, announced yesterday that it has closed a $6.05 million Series A round.
Investors in the company include ServiceNow founder Fred Luddy, Buckingham Capital Management Chairman Larry Leeds Jr., Metalab founder Andrew Wilkinson, CEO of Venturehouse Mark Ein, and others.
The app — which...
June 20, 2018
The US’s struggle with opioid addiction rages on, and Facebook seems to have heard critics’ warnings about social media’s role in the epidemic. During an event yesterday, representatives from the company announced that users trying to purchase opioids or find addiction treatment through their platform will be redirected to information about a federal crisis helpline, according to reports from...
June 14, 2018
DyAnsys, a medical device company specializing in the autonomic nervous system, announced this week that it has received FDA approval for a wearable auricular neurostimulation device designed to treat symptoms of opioid withdrawal.
The device, called Drug Relief, is now available to providers in the US, and is distributed in the EU by the DyAnsys’ European branch.
"This device offers hope to...
October 18, 2017
Pear Therapeutics announced today that reSET-O, a digital therapeutic for opioid use disorder, has received an Expedited Access Pathway (EAP) designation from the FDA. The EAP designation doesn't mean that the FDA has cleared the product, only that it has committed to fast-tracking it through the clearance process because of its timely public health value.
“The opioid epidemic continues to...
June 28, 2017
Baltimore-based emocha Mobile Health has been awarded a $1.7 million Fast Track Small Business Innovation Research award by the National Institute on Drug Abuse (NIDA). The company will use the grant for a feasibility study of its digital direct observation therapy tech.
Emocha is an acronym for “electronic mobile comprehensive health application”. The company has been developing an app for...